Latest Hospitality News

Iris Cairns Property Pty Ltd has lodged a bidder’s statement for an all-cash $3.87 per unit takeover offer for Reef Casino Trust, securing unanimous recommendation from the trust’s board and major unitholders. The offer, representing a significant premium, awaits regulatory approvals and closes in March 2026.

Steamships Trading Company Limited reported a modest 1.7% dip in half-year profit despite a 6.7% rise in revenue, driven by strong divisional performances and significant property gains. The company’s increased capital investment and cautious outlook highlight ongoing challenges and opportunities in Papua New Guinea’s economic landscape.

Skin Elements Limited reported a 13% revenue increase and a 20% reduction in net loss for FY2025, as it progresses commercial roll-out of its natural biotech products including ECO-Nurture and SuprCuvr.

Echo IQ Limited reported a sharp increase in losses for FY25 despite revenue growth, while securing FDA clearance and expanding its AI-driven cardiology platform across major US networks.

IMEXHS reported a steady first half of FY25 with revenue up 4% and annualised recurring revenue climbing 11%, driven by strong adoption of its Aquila+ radiology platform and strategic capital raising.

Resonance Health Limited reported a 29% revenue increase to $11.07 million for FY25 but posted a net loss of $1.73 million, reflecting strategic investments and expansion in clinical trial services.

Constellation Technologies Limited has reported a 34% revenue increase and a return to profitability in FY25, driven by strong adoption of its IoT-based food safety solutions across multiple sectors. The company is scaling its innovative Callisto platform and hardware offerings to capture broader market opportunities.

Next Science reports a 42% improvement in adjusted EBITDA loss for 1H FY25 despite a 7% dip in product sales, while shareholders approve a major asset sale to OSARTIS GmbH.

Tryptamine Therapeutics reported a $5.33 million loss for FY25 while progressing key clinical trials of its psychedelic therapies and strengthening its leadership team. The company secured $6 million in funding and launched a world-first trial targeting Binge Eating Disorder.

Memphasys Limited reported a net loss of AUD 4.94 million for FY25 while accelerating commercial efforts for its Felix System and advancing its RoXsta diagnostics platform.

PainChek Limited reported a 24% revenue increase to $4.8 million for FY25, narrowing its net loss by 7%, while progressing toward FDA clearance for its Adult PainChek App in the US and launching its Infant App in Australia.

Mesoblast reports a strong FY2025 financial performance driven by the commercial launch of Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in children. The company is advancing multiple clinical programs targeting inflammatory diseases, heart failure, and chronic low back pain.